Moreover, our data strengthen the concept that the presence of a functionally active FOXO3a binding site for gene expression of cell cycle regulators induces consequent cell fate determination via FOXO3a-mediated autophagic flux and NLRP3 inflammasome activation, suggesting a potential therapeutic target in MDS and myeloid malignancies. This evidence concerns the gene FOXO3 and myelodysplastic syndrome.